Connect Biopharma Holdings (CNTB) Return on Capital Employed (2025 - 2026)
Connect Biopharma Holdings (CNTB) posted Return on Capital Employed of 161.45% for Q1 2026, down 33.73% sequentially from 120.72% in Q4 2025, and down 13739.0% YoY from N/an in Q1 2025.
Connect Biopharma Holdings (CNTB) Return on Capital Employed (2025 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Return on Capital Employed for 2 years, with the latest figure at 161.45% in Q1 2026.
- Quarterly Return on Capital Employed fell 13739.0% year-over-year to 161.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.45% (down 13739.0% YoY) and the FY2025 annual result came in at 89.25%, down 6805.0% from the prior year.
- Return on Capital Employed fell to 161.45% in Q1 2026 per CNTB's latest filing, from 120.72% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 24.05% in Q1 2025 and troughed at 161.45% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 7.88% |
| 10 | Connect Biopharma Holdings | 144.32 Mn | 144.32 Mn | - | -198.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -198.53% |
| Mar 31, 2026 | -161.45% |
| Dec 31, 2025 | -120.72% |
| Sep 30, 2025 | -82.00% |
| Jun 30, 2025 | -62.80% |
| Mar 31, 2025 | -24.05% |